Late incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves  by Ruel, Marc et al.
Late incidence and predictors of persistent or recurrent
heart failure in patients with aortic prosthetic valves
Marc Ruel, MD, MPHa,b
Fraser D. Rubens, MDa
Roy G. Masters, MDa
Andrew L. Pipe, MDa
Pierre Be´dard, MDa
Paul J. Hendry, MDa
B. Khanh Lam, MD, MPHa
Ian G. Burwash, MDc
William G. Goldstein, MDa
Maurice P. Brais, MDa
Wilbert J. Keon, MDa
Thierry G. Mesana, MD, PhDa
Background: We examined factors associated with persistent or recurrent congestive
heart failure after aortic valve replacement.
Methods: Patients who underwent aortic valve replacement with contemporary
prostheses (n  1563) were followed up with annual clinical assessment and
echocardiography. The effect of demographic, comorbid, and valve-related vari-
ables on the composite outcome of New York Heart Association class III or IV
symptoms or congestive heart failure death after surgery was evaluated with
stratified log-rank tests, Cox proportional hazard models, and logistic regression.
Factors associated with all-cause death were also examined. Prediction models were
bootstrapped 1000 times.
Results: Total follow-up was 6768 patient-years (mean, 4.3  3.3 years; range, 60
days to 17.1 years). Freedom from congestive heart failure or congestive heart
failure death was 98.6%  0.3%, 88.6%  1.0%, 73.9%  2.3%, and 45.2% 
8.5% at 1, 5, 10, and 15 years, respectively. Age, preoperative New York Heart
Association class, left ventricular grade, atrial fibrillation, coronary artery disease,
smoking, and redo status predicted congestive heart failure after surgery (all P 
.05). Larger prosthesis size and effective orifice area, both absolute and indexed for
body surface area, were independently associated with freedom from congestive
heart failure. Increased transprosthesis gradients were predicted by prosthesis-
patient mismatch and were associated with congestive heart failure after surgery.
Mismatch defined as an effective orifice area/body surface area of 0.80 cm2/m2 or
less was a significant predictor of congestive heart failure events after surgery, but
mismatch defined as an effective orifice area/body surface area of 0.85 cm2/m2 or
less was not. Small prosthesis size and mismatch were not significantly associated
with all-cause mortality.
Conclusions: These analyses identify independent predictors of congestive heart
failure symptoms and congestive heart failure death late after aortic valve replace-
ment and indicate that prosthesis size has a significant effect on this cardiac end
point, but not on overall survival after aortic valve replacement.
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Acommon goal of heart valve replacementis to prevent or cure symptoms of heartfailure and decrease the likelihood ofheart failure–related death. An extensivebody of literature has defined the optimaltiming of valve replacement on the basis
of symptoms and cardiac function to achieve this goal in the
highest proportion of patients while minimizing the effects
of operation and prosthesis-related complications on sur-
vival and quality of life.1
Few studies have systematically examined the effects of
patient- and prosthesis-related characteristics on the occur-
rence of heart failure after valve replacement. Surgeons and
cardiologists alike know that heart failure is not always
cured or prevented by valve replacement.1 Knowing the risk
factors for heart failure after valve replacement could prove
useful for determining a patient’s postoperative prognosis
and assist in clinical decision making.
One factor of interest is the ability of the replacement
prosthesis to allow unimpeded blood flow. This parameter is
potentially modifiable and is related to the size and type of
prosthesis implanted at operation. Many surgeons intuitively
perceive that prosthesis size and type may influence long-term
clinical outcome after aortic valve replacement. Expectations
may be hampered, however, by technical limitations imposed
by the size of the native annulus after excision of the diseased
valve. In patients with a small native aortic annulus, a pros-
thesis with a larger effective orifice area (EOA) may be im-
planted by performing root enlargement2 or root replacement3
or by using a stentless valve,4,5 but these techniques are sur-
gically more challenging and may be associated with increased
morbidity,6,7 particularly in inexperienced hands.
The approach to this dilemma remains controversial.
Recent data suggest that the long-term consequences of
small aortic prosthesis implantation may be less than antic-
ipated with respect to all-cause mortality, thus suggesting
that complex alternative procedures may be unnecessary.8
Other data suggest that accepting this predicament without
correction may lead to placement of a small prosthesis with
resultant impediment of blood flow and less recovery of left
ventricular function, which could affect quality of life and
freedom from cardiac death.9 For these reasons, we aimed at
elucidating whether aortic prosthesis size, among other fac-
tors, has an independent effect on freedom from postoper-
ative heart failure.
This study, therefore, examines the effect of patient- and
prosthesis-related factors on the occurrence of clinical heart
failure after surgery in a cohort of patients followed up after
aortic valve replacement.
Methods
Patients and Follow-up
Adult patients (18 years of age) who underwent aortic valve
replacement between 1976 and 2001 at the University of Ottawa
Heart Institute were followed up annually in a dedicated valve
clinic. All patients had a history focused on the determination of
functional status and the occurrence of valve-related complica-
tions, physical examination, electrocardiogram, chest radio-
graph, complete blood count, serum chemistries, and interna-
tional normalized ratio determinations when applicable.
Because of the potential effect of the prosthesis on the outcome of
interest, patients who received valves that have since been with-
drawn from the North American market, such as the Ionescu-
Shiley (Shiley, Inc, Irvine, Calif) or Medtronic Intact (Minneapo-
lis, Minn) prostheses, were excluded from the analyses. The
studied cohort included 1683 adult patients who underwent re-
placement of the aortic valve with prostheses that are still com-
mercially available today and who survived the perioperative
period. Of these 1683 patients, 119 were lost to follow-up or died
during the second postoperative month, and 1563 (92.9%) were
followed up as outpatients after a minimum of 60 days after
surgery.
The preoperative characteristics of the cohort are presented in
Table 1. Total follow-up was 6768 patient-years, with a mean
duration of 4.3  3.3 years (range, 60 days to 17.1 years).
Seventy-nine percent of patients had an average of 3.5 postoper-
ative transthoracic echocardiograms performed on an annual basis
at our institution, and these were interpreted by 1 of 4 physicians,
who determined mean and peak transprosthesis gradients accord-
ing to the recommendations of the American Society of Echocar-
diography.
TABLE 1. Prevalence and mean values of preoperative
variables, by type of prosthesis
Variable
Mechanical
(n  873)
Bioprosthetic
(n  690)
Female sex 30.6% 34.8%
Age at operation (y) 59.7 11.9 68.9 13.3*
Body surface area (m2) 1.85 0.23 1.86 0.26
NYHA class
I 25.2% 27.7%
II 33.3% 27.5%
III 26.4% 29.8%
IV 15.1% 15.0%
Left ventricular grade
1 41.7% 55.0%*
2 25.6% 21.7%
3 21.1% 15.5%
4 11.6% 7.8%
LVEDP (mm Hg) 21.5 9.1 18.9 7.9
Coronary artery disease 33.9% 37.1%
Chronic atrial fibrillation 5.2% 3.3%
Previous aortic valve replacement 21.8% 6.4%*
Operative indication
Predominant stenosis 51.6% 74.9%*
Predominant insufficiency 39.1% 15.3%*
Values are reported as mean  SD or %.
LVEDP, Left ventricular end-diastolic pressure; NYHA, New York Heart
Association.
*P  .05 versus patients with mechanical valves.
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Types of Prostheses
Table 2 shows the types of valve prostheses implanted in the study
population. All patients received prostheses that were still com-
mercially available as of this writing and that were implanted and
oriented according to the manufacturer’s recommendations. Be-
cause of the continued availability of the St Jude Medical (St Jude
Medical, Inc, St Paul, Minn), Medtronic Hall (Medtronic), and
CarboMedics (Sulzer Carbomedics, Inc, Austin, Tex) mechanical
valves and the discontinuation of several models of bioprostheses
over the past 2 decades, a predominance of mechanical valves is
found in the study cohort.
Definition of Heart Failure
Heart failure after aortic valve replacement was defined as the
composite end point of (1) New York Heart Association (NYHA)
functional class III or IV for more than 4 consecutive weeks or (2)
death where the primary or main contributing diagnosis was con-
gestive heart failure (CHF). Clinical impressions were corrobo-
rated with physical examination, chest radiograph, electrocardio-
gram, and echocardiography findings when available. Cases of
primary nonstructural dysfunction resulting from severe paraval-
vular leaks, valve thrombosis, or endocarditis were excluded as
heart failure events for the purposes of this study. Other prosthesis-
related complications were recorded according to the “Guidelines
for Reporting Morbidity and Mortality After Cardiac Valvular
Operations.”10,11
Statistical Analyses
Data entries. Data were imported and analyzed in Intercooled
Stata version 8 (Stata, College Station, Tex). Patients were cen-
sored at the time of their last follow-up visit if they had not
experienced at least 1 episode of NYHA functional class III or IV
for 4 weeks or more or had died from a CHF-related event. Deaths
from an unknown cause were not considered to result from CHF
and were treated as a censored event if the patient had not previ-
ously experienced NYHA class III or IV symptoms. When missing
data were encountered, they were not replaced or imputed, and
analyses were performed with a sample size equal to the number of
complete entries.
Prosthesis size. The model and manufacturer valve size of the
implanted prosthesis was available for all patients. Because of
variations in size nomenclature between manufacturers and mod-
els, the valve size value of each prosthesis model and size was
imputed with (1) its internal diameter (based on work by Christakis
and associates12 and supplemented with data provided by the valve
manufacturer) and (2) its echocardiographic in vivo EOA reported
in the literature from patients with normally functioning prosthe-
ses.13 If more than 1 value of in vivo EOA was published for a
given prosthesis type and size, the average of the values was used.
Transprosthesis gradient. The aortic peak and mean
transprosthesis gradients determined at the time follow-up echo-
cardiography were used to examine their effect on the heart failure
hazard, both as a continuous variable and as an arbitrary dichoto-
mous parameter defined by a gradient value at or above the 90th
percentile. Values from the last echocardiographic examination
available before demonstration of structural valvular deterioration
or recurrent heart failure symptoms were used, except in patients
with persistent heart failure symptoms after operation, in whom
values from the first postoperative outpatient echocardiographic
examination were used.
Cumulative incidence of heart failure. Nonparametric esti-
mates of overall, non–risk-adjusted freedom from the composite
heart failure end point over time were determined by the method of
Kaplan and Meier. Risk-adjusted and stratified estimates of free-
dom from CHF death and all-cause death were also generated.
Survival and failure rates are reported as mean  SEM (95%
confidence interval lower bound, 95% confidence interval upper
bound).
Univariate analyses. Possible predictors for CHF were indi-
vidually tested for equality of freedom from heart failure with a
log-rank test. Effect estimates and P values were used to guide
multivariate model selection and are not reported.
Multivariate analyses. For heart failure and death hazard, the
proportional hazard assumption was tested with generalized Cox-
Snell residuals, with ln[ln(survival)] probabilities, and by ad-
dressing, in the case of continuous variables, whether a significant
interaction with time was present. Semiparametric Cox propor-
tional hazards models were developed by incorporating variables
that had a P value of .05 or less on univariate analysis and by
forcing into each model patient- and prosthesis-related variables
that could constitute possible confounders regardless of their uni-
variate P value. Variables used in the models are reported in
Tables 3 and 4. To account for positive or negative confounding,
no automated model-selection procedure was used, and all re-
ported variables were used simultaneously unless collinearity was
present (defined as Spearman’s rank correlation coefficient 0.30
and P value  .005 between 2 variables). Each model was eval-
uated with a score test and rejected if P was 0.05 or higher. The
effect of prosthesis size measures on the cumulative incidence of
heart failure symptoms and CHF-related death at 1, 5, and 10 years
was examined with logistic regression by using the same covari-
ates as in the Cox proportional hazards models.
Bootstrapped simulations. Each proportional hazards model
was subjected to 1000 bootstrap replications by using random
samples generated from and consisting of the same number of
patients as the original model.14 Each simulation sample was
TABLE 2. Implanted aortic prostheses and manufacturer
valve size
Variable
Number implanted
(median size; range [mm])
Mechanical
St Jude Medical standard 274 (23; 19–33)
St Jude Medical HP 80 (23; 19–27)
Medtronic Hall 280 (23; 20–29)
CarboMedics 225 (25; 21–31)
MCRI On-X 14 (23; 19–27)
Bioprosthetic
Medtronic Hancock II 408 (23; 21–31)
Medtronic Hancock modified
orifice
126 (21; 19–29)
Homograft 79 (22; 18–26)
Edwards Perimount 60 (23; 21–27)
Stentless porcine 10 (25; 21–27)
Carpentier-Edwards standard 7 (23; 19–31)
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analyzed as a new patient population, and coefficients of the
models were adjusted for confounding. Bootstrap estimates of SE,
bias, and 95% confidence intervals were calculated for each co-
variate by using a bias-corrected method derived from the 1000
replications.
Results
Cumulative Incidence of Heart Failure Events After
Valve Replacement
Freedom from the composite outcome of NYHA functional
class III or IV symptoms or CHF death after aortic valve
replacement was 98.6%  0.3%, 88.6%  1.0%, 73.9% 
2.2%, and 45.2%  8.5% at 1, 5, 10, and 15 years, respec-
tively. Figure 1 shows the freedom from NYHA class III or
IV symptoms not leading to CHF-related death (Figure 1,
A), the freedom from CHF-related death (Figure 1, B), and
the freedom from all-cause death (Figure 1, C) in patients
with mechanical and bioprosthetic aortic valves.
TABLE 3. Predictors of NYHA class III or IV symptoms or
CHF-related death
Variable
Adjusted
hazard ratio 95% CI P value
Significant independent predictors
Age 65 y 1.62 1.07, 2.44 .022
Atrial fibrillation 3.18 1.71, 5.92 .001
Preoperative NYHA class* 1.38 1.14, 1.67 .001
Preoperative left ventricular
grade*
1.74 1.30, 2.33 .001
Preoperative diastolic
pulmonary artery pressure
(per mm Hg)*
1.01 1.00, 1.02 .030
Coronary artery disease 1.55 2.11, 5.12 .031
Smoking 3.29 1.85, 3.60 .001
Redo aortic valve replacement 1.67 1.15, 2.42 .007
Tricuspid insufficiency 3.61 1.09, 12.0 .036
Manufacturer valve size (per 1
size increase)†
0.81 0.67, 0.99 .037
Internal valve diameter (per
mm)†
0.90 0.82, 0.99 .046
In vivo effective orifice area
(per cm2)†
0.41 0.17, 0.97 .042
Mismatch defined as 0.75
cm2/m2†‡
1.64 1.01, 2.56 .047
Mismatch defined as 0.80
cm2/m2†‡
1.61 1.01, 2.57 .044
Peak transprosthesis gradient
(per mm)†
1.03 1.02, 1.05 .001
Mean transprosthesis gradient
(per mm)†
1.06 1.03, 1.09 .001
Peak transprosthesis gradient
90th percentile†
2.48 1.32, 4.68 .005
Mean transprosthesis gradient
90th percentile†
2.84 1.49, 5.40 .001
Nonsignificant variables included in the model
Mismatch defined as 0.85
cm2/m2†‡
1.20 0.79, 1.82 .40
Body surface area 1.50 0.68, 3.28 .31
Diabetes mellitus 1.02 0.50, 2.10 .95
History of stroke 0.94 0.12, 7.45 .95
Bioprosthetic (vs mechanical)
valve
0.67 0.43, 1.06 .09
Operative indication for
predominant AI
0.99 0.61, 1.61 .97
AI, Aortic insufficiency; NYHA, New York Heart Association; CI, confidence
interval.
*,†Collinear variables that were successively but not simultaneously in-
cluded in the model.
‡Models that included mismatch terms (determined by the ratio of the
prosthesis’s in vivo effective orifice area divided by the patient’s body
surface area) did not also incorporate body surface area as an additional
term.
TABLE 4. Predictors of all-cause death
Variable
Adjusted
hazard ratio 95% CI P value
Significant independent predictors
Age (per year) 1.05 1.02, 1.07 .001
Atrial fibrillation 2.39 1.10, 5.18 .028
Preoperative NYHA class* 1.24 1.01, 1.52 .037
Preoperative left ventricular
grade*
1.41 1.00, 1.99 .048
Preoperative diastolic pulmonary
artery pressure (per mm Hg)*
1.01 1.00, 1.02 .030
Coronary artery disease 1.62 1.05, 2.50 .029
Number of pack-years smoked
(per pack-year)
1.02 1.01, 1.04 .006
Insulin-dependent diabetes
mellitus
3.32 1.02, 11.2 .047
Nonsignificant variables included in the model
Redo aortic valve replacement 1.10 0.62, 1.97 .74
Tricuspid insufficiency 1.13 0.15, 8.42 .90
Manufacturer valve size (per 1
size increase)†
1.00 0.81, 1.23 .97
Internal valve diameter (per
mm)*
1.02 0.92, 1.13 .77
In vivo effective orifice area (per
cm2)*
0.41 0.15, 1.14 .09
Mismatch defined as 0.75 cm2/
m2*†
1.27 0.77, 2.07 .34
Mismatch defined as 0.80 cm2/
m2*†
1.42 0.88, 2.31 .15
Mismatch defined as 0.85 cm2/
m2*†
1.34 0.88, 2.02 .17
Body surface area 1.32 0.57, 3.04 .52
Bioprosthetic (vs mechanical)
valve
1.10 0.70, 1.73 .69
Operative indication for
predominant AI
1.01 0.58, 1.78 .96
AI, Aortic insufficiency; NYHA, New York Heart Association; CI, confidence
interval.
*Collinear variables that were successively but not simultaneously in-
cluded in the model.
†Models that included mismatch terms (determined by the ratio of the
prosthesis’s in vivo effective orifice area divided by the patient’s body
surface area) did not also incorporate body surface area as an additional
term.
Surgery for Acquired Cardiovascular Disease Ruel et al
152 The Journal of Thoracic and Cardiovascular Surgery ● January 2004
A
CD
Risk Factors for Heart Failure
Patient-related factors. Table 3 displays the risk factors
for heart failure late after aortic valve replacement. Signif-
icant independent predictors included age over 65 years
(hazard ratio [HR], 1.6), atrial fibrillation (HR, 3.2), preop-
erative functional class (HR, 1.4 per class increase), left
ventricular grade (HR, 1.7 per unit increase), pulmonary
artery diastolic pressures (HR, 1.01 per millimeter increase),
coronary artery disease at the time of operation (HR, 1.6),
smoking (HR, 3.3), redo aortic valve replacement (HR, 1.7),
and moderate to severe tricuspid insufficiency at follow-up
echocardiography (HR, 4.5).
Prosthesis-related factors. Regarding aortic prosthesis
size and prosthesis-patient mismatch, in patients with aortic
prostheses, prosthesis size predicted freedom from heart
failure after valve replacement. An independent linear effect
was observed with respect to manufacturer prosthesis size
(HR, 0.8 per increase of 1 valve size), internal prosthesis
Figure 1. Cumulative incidence of heart failure events and death. Kaplan-Meier estimates of the freedom from
NYHA class III or IV symptoms (A), CHF-related death (B), and all-cause death (C) in patients with aortic
mechanical and bioprosthetic valves. *P  .02 versus patients with mechanical valves.
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diameter (HR, 0.9 per millimeter increase), and in vivo
EOA (HR, 0.6 per square centimeter increase). Each of
these associations was statistically significant, regardless of
whether body surface area (BSA) was simultaneously ac-
counted for in the model.
Of 1226 patients in whom the prosthesis EOA indexed
for BSA (iEOA) could be determined, 392 (32.0%) had an
iEOA at or less than 0.85 cm2/m2, 315 (25.7%) had an
iEOA at or less than 0.80 cm2/m2, and 232 (18.9%) had an
iEOA at or less than 0.75 cm2/m2. These 3 possible defini-
tions of the prosthesis-patient mismatch concept were ex-
amined in the multivariate models (Tables 3 and 5): mis-
match defined both as iEOA less than or equal to 0.75
cm2/m2 and as iEOA less than or equal to 0.80 cm2/m2
independently predicted decreased freedom from heart fail-
ure events after aortic valve replacement (HR, 1.6), but
mismatch defined as iEOA less than or equal to 0.85 cm2/m2
did not have a significant effect on this outcome.
The effect of aortic prosthesis size and mismatch on the
cumulative incidence of CHF-related events at 1, 5, and 10
years is shown in Table 5. All measures of prosthesis size
(with the exception of the internal prosthesis diameter at 5
years) predicted freedom from heart failure at 1 and 5 years
after aortic valve replacement, but none had an effect at 10
years after valve replacement. Mismatch defined at both
thresholds of iEOA less than or equal to 0.75 cm2/m2 and
iEOA less than or equal to 0.80 cm2/m2 was predictive of a
decreased freedom from heart failure at 5 years (odds ratio,
2.1), but mismatch defined at an iEOA less than or equal to
0.85 cm2/m2 again was not. No prosthesis size or mismatch
parameter was predictive of freedom from heart failure at 10
years after valve replacement.
The effect of upper (0.85 cm2/m2) and lower (0.75 cm2/
m2) mismatch thresholds on the risk-adjusted incidence of
CHF-related death is presented in Figure 2. Patients with an
iEOA between 0.75 and 0.85 cm2/m2 had an equivalent risk
of CHF-related death to those without any form of mis-
match (HR 0.9 vs nonmismatch patients; P  .790); how-
ever, in patients with an iEOA of 0.75 cm2/m2 or less, a
trend toward a higher risk of CHF-related death was ob-
served (HR 1.8 vs nonmismatch patients; P  .109).
The median transprosthesis peak and mean gradient for
patients with an aortic prosthesis were 26 and 15 mm Hg,
respectively, and the 90th percentile values for peak and
mean aortic gradients were 50 and 29 mm Hg, respectively.
Aortic peak and mean gradients were significantly higher in
patients with mismatch defined by using any 1 of the 3
definitions examined in the multivariate models. For in-
stance, in patients with an aortic iEOA less than or equal to
0.80 cm2/m2, the median peak and mean aortic gradients
were 29 and 16 mm Hg, respectively, versus 26 and 14 mm
Hg, respectively, in those without mismatch (P  .002).
Compared with those with an iEOA greater than 0.80 cm2/
m2, patients with an aortic iEOA less than or equal to 0.80
cm2/m2 had a 1.79 relative risk of having an aortic peak
transprosthesis gradient at or greater than the cohort’s 90th
percentile value (P  .01).
Peak and mean transprosthesis gradients had a significant
negative effect on freedom from heart failure after valve
replacement, both as a linear relationship (HR, 1.03 and
1.06 per millimeter increase in peak and mean gradient,
respectively; P  .001) and as a dichotomous predictor
defined by a gradient at or more than the 90th percentile
value of the cohort (HR, 2.5 and 2.8 for increased peak and
mean gradients, respectively; P  .005).
Risk Factors for All-Cause Death
Table 4 displays risk factors for all-cause death late after
aortic valve replacement in the study cohort. Significant
independent predictors were age, atrial fibrillation, preop-
erative functional class, left ventricular grade, pulmonary
artery diastolic pressures, coronary artery disease, the num-
ber of pack-years smoked, and insulin-dependent diabetes.
Although a trend in predicting all-cause mortality was ob-
served for EOA (HR, 0.4 per square centimeter increase; P
 .09) and prosthesis-patient mismatch defined as EOA/
BSA less than or equal to 0.80 cm2/m2 (HR, 1.4 vs patients
with EOA/BSA 0.80 cm2/m2; P  .15), no significant
TABLE 5. Effect of aortic prosthesis size on the cumulative incidence of NYHA class III or IV or CHF death at 1, 5, and 10 y
after aortic valve replacement
Variable 1-y Odds ratio 5-y Odds ratio 10-y Odds ratio
Manufacturer valve size (per unit) 0.72 (0.54, 0.98; 0.037) 0.78 (0.59, 1.01; 0.07) 0.77 (0.54, 1.08; 0.14)
Internal valve diameter (per mm) 0.85 (0.73, 0.99; 0.043) 0.92 (0.80, 1.05; 0.23) 0.92 (0.77, 1.10; 0.37)
In vivo effective orifice area (per cm2) 0.40 (0.18, 0.87; 0.021) 0.26 (0.07, 0.95; 0.041) 0.44 (0.17, 1.15; 0.09)
Mismatch defined as 0.75 cm2/m2 2.07 (0.96, 4.44; 0.06) 2.09 (1.03, 4.27; 0.043) 1.98 (0.71, 5.51; 0.19)
Mismatch defined as 0.80 cm2/m2 2.45 (1.17, 5.12; 0.017) 2.08 (1.04, 4.15; 0.038) 1.93 (0.77, 4.82; 0.16)
Mismatch defined as 0.85 cm2/m2 1.80 (0.94, 3.42; 0.08) 1.41 (0.78, 2.54; 0.26) 1.48 (0.69, 3.16; 0.67)
Other variables included in the model were age over 65 y, atrial fibrillation, preoperative NYHA class, coronary disease, smoking, history of stroke, diabetes
mellitus, operative indication for predominant aortic insufficiency (vs stenosis), redo aortic valve replacement, bioprosthetic (vs mechanical) valve, tricuspid
insufficiency, and body surface area. Data presented as odds ratio (lower 95% confidence limit, upper 95% confidence limit; P value). NYHA, New York
Heart Association.
Surgery for Acquired Cardiovascular Disease Ruel et al
154 The Journal of Thoracic and Cardiovascular Surgery ● January 2004
A
CD
independent effect of prosthesis size on crude survival was
demonstrated.
Discussion
This study identified risk factors for persistent or recurrent
heart failure after aortic valve replacement from a cohort of
patients who were prospectively followed up after surgery.
Risk factors for the composite outcome of heart failure
symptoms or death from heart failure after aortic valve
replacement were age older than 65 years, atrial fibrillation,
advanced preoperative NYHA class, increased preoperative
diastolic pulmonary artery pressures, left ventricular grade,
coronary artery disease, smoking, redo aortic valve replace-
ment, concomitant tricuspid insufficiency, smaller prosthe-
sis size, postoperative transprosthesis gradient, and prosthe-
sis-patient mismatch defined as either iEOA less than or
equal to 0.75 cm2/m2 or iEOA less than or equal to 0.80
cm2/m2, which resulted in an increase in estimated heart
failure risk of approximately 60%. There was also a trend
for prosthesis-patient mismatch defined as iEOA less than
or equal to 0.75 cm2/m2 to predict a decreased freedom from
the specific hard end point of CHF death after valve replace-
ment. However, prosthesis-patient mismatch in its classic
definition, ie, iEOA less than or equal to 0.85 cm2/m2, was
not associated with an increased incidence of CHF symp-
toms, CHF death, or their combined occurrence. Valve size
and mismatch indicators also significantly predicted the
cumulative incidence of heart failure at 1 and 5 years after
aortic valve replacement, at which time patients in mis-
match had twice the odds of having had heart failure events
compared with those not in mismatch, but not at 10 years,
where it is possible that competing risks related to biopros-
thesis structural deterioration, progression of underlying left
ventricular dysfunction, or development of coronary artery
disease may have diminished the overall effect of prosthesis
size and mismatch on freedom from CHF.
Prosthesis size and mismatch were not found to be inde-
pendently predictive of the incidence of all-cause death in
this study. Despite all-cause mortality being a robust and
easily interpretable end point, it is limited as a specific
indicator by the plethora of confounding and contributing
factors and by the availability of medical therapy for the
palliation of mild to moderate heart failure. In an elderly
patient population, such as in this cohort, competing causes
of death such as coronary disease, valve-related complica-
tions, cancer, and others may also have diluted the effect of
patient-prosthesis mismatch on all-cause mortality after aor-
tic valve replacement. A primary end point of CHF was
therefore chosen a priori as a more specific indicator of
long-term outcome after valve replacement, because CHF is
a relevant clinical condition that translates into decreased
quality of life for the patient and directly reflects on the
success of valve replacement.
Several of the risk factors for CHF after valve replace-
ment identified in this study have heightened relevance in
that they are potentially modifiable. One patient-related
factor is smoking, and although the possible benefits of
smoking cessation in valve patients are only suggested by
the results of this study, for this reason as well as for other
health benefits, patients should be strongly encouraged to
refrain from smoking after valve replacement. Other mod-
ifiable risk factors relate to clinical decision making and
surgical technique, because advanced preoperative NYHA
functional class before operation, persistent tricuspid regur-
gitation after surgery, chronic atrial fibrillation, small pros-
thesis size, and prosthesis-patient mismatch (iEOA  0.80
cm2/m2) were identified as independent predictors of heart
failure after valve replacement. It is possible, although
undetermined from these data, that current trends in the
treatment of patients with valve disease—such as the refer-
ral of patients for valve repair or replacement at an earlier
symptomatic stage before left ventricular dysfunction oc-
curs,1 the renewed emphasis on the concomitant surgical
treatment of tricuspid valve insufficiency during left heart
valve operations,15 the expanded indications for concomi-
tant atrial fibrillation surgery,16 and the avoidance of aortic
prosthesis-patient mismatch by the selective use of stentless
valves, homografts, and root enlargement procedures13—
Figure 2. Effect of prosthesis-patient mismatch on the incidence
of CHF-related death after aortic valve replacement, adjusted for
age, preoperative NYHA class, smoking, atrial fibrillation, and
coronary disease. Patients with an indexed effective orifice area
(iEOA) between 0.75 and 0.85 cm2/m2 had an equivalent incidence
of CHF-related death compared with those with an iEOA of more
than 0.85 cm2/m2; however, a trend toward an increased risk of
CHF death was observed in patients with an iEOA equal to or less
than 0.75 cm2/m2.
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may have a beneficial effect on freedom from heart failure
after aortic valve replacement.
Whether aortic prosthesis-patient mismatch is relevant or
not has been a subject of intense controversy in the cardiac
literature. One inherent difficulty in answering this question
relates to the fact that surgical decision making and con-
founding by indication17 may bias against patients with
small aortic prostheses with respect to operative mortality,
all-cause survival, and long-term functional symptoms.9 In
this situation, the surgeon’s choice of prosthesis type and
size during valve replacement is heavily influenced by the
perceived balance between the increased perioperative risk
of the more complex operation needed to avoid a potentially
suboptimal late clinical outcome due to a small prosthesis,
and the chances of the patient experiencing meaningful
long-term survival and quality of life. Perioperative out-
comes may be particularly susceptible to confounding by
indication, and consequently this study focused on func-
tional cardiac outcomes in patients who survived aortic
valve replacement. Confounding was also reduced by the
use of bootstrapped regression models in which multiple
potential confounders were simultaneously accounted for,
regardless of their P value on univariate analysis.
Our findings support the concept that there is a minimal
threshold in prosthesis size related to the patient’s BSA,
somewhere near an iEOA of 0.75 or 0.80 cm2/m2, beyond
which optimal cardiac recovery is less likely to occur after
valve replacement. The concept of prosthesis-patient mis-
match was first introduced by Rahimtoola18 in 1978 as a
condition in which the in vivo prosthetic valve EOA is less
than that of the native human valve. The physiologic se-
quelae of mismatch were subsequently proposed to relate to
persistent valve gradients on the basis of in vitro studies
conducted by Dumesnil and Yoganathan,19 who demon-
strated an exponential relationship between mean transpros-
thetic pressure gradient and iEOAs for aortic bioprostheses
in an in vitro physiologic pulse-duplicator system. Their
results fostered the recommendation that iEOA should ide-
ally not be less than 0.9 to 1 cm2/m2 for aortic bioprostheses
to minimize residual postoperative transprosthetic peak
pressure gradients and led to the premise that there may be
a correlation between the decrease in transvalvular gradient
and the clinical improvement seen after surgery.20,21
Determining mismatch on the basis of postoperative
echocardiographic gradients may, however, be flawed, be-
cause it may not adequately take into account patients in
whom persistent left ventricular dysfunction due to the
intrinsically stenotic valve may perpetuate a decreased car-
diac output situation with failure to generate the expected
high transprosthetic gradients.22 This limitation may explain
previous data reported by Hanayama and associates,23 who
did not demonstrate a difference in clinical outcome in
patients with high transprosthesis gradients after aortic
valve replacement. Although our study examined the effect
of postoperative gradient and found transprosthesis gradi-
ents to be both predicted by patient-prosthesis mismatch and
predictive of a decreased freedom from postoperative heart
failure, postoperative gradients may constitute a less than
optimal method to define prosthesis-patient mismatch, be-
cause gradients are measured after valve replacement has
taken place and may be unreliable in the setting of persistent
left ventricular dysfunction.
Work from Medalion and colleagues8 has indicated that
small prosthesis size is not a predictor of long-term out-
come, and other authors have also failed to show a corre-
lation between mismatch, early or late all-cause mortality,
and morbidity.24-26 In the studies of Knez and associates24
and Medalion and associates,8 outcomes were, however,
correlated with indexed measures of the geometric internal
orifice area (GIOA). The GIOA was derived on the basis of
the internal area calculated from the documented internal
valve orifice diameter. The documented internal valve ori-
fice diameter either was provided from the manufacturer or
was measured by using microcalipers.12 GIOA is, however,
a 2-dimensional measure that does not take into account the
other characteristics of a valve that may contribute signifi-
cantly to minimizing the effective valve orifice, such as
valve height and leaflet structures within the valve. For
these reasons, the in vivo EOA derived from patients with
normally functioning valves is superior and more clinically
relevant.13 Differences between GIOA and EOA may also
explain why there is such a discrepancy in the incidence of
prosthesis-patient mismatch among many of the available
studies, because previous studies have shown that the ratio
between the GIOA and the EOA may significantly vary
depending on the type of prosthesis.27,28 In a study from
Pibarot and colleagues,29 the incidence of mismatch was
71% for stented prostheses and 29% for stentless prostheses,
more within the range observed in our population, with an
incidence of 32%, and in contrast to the study from Med-
alion and colleagues,8 in which mismatch was present in
less than 1% of patients with a calculated GIOA threshold
of less than 0.85 cm2/m2.
Selection Bias and Confounding
This study was not randomized, and it is possible that
despite the use of specific CHF end points and multivariate
bootstrapped methods, confounding by indication, selection
bias, or unidentified confounders may have influenced the
results, especially in patients in whom a smaller aortic
prosthesis was implanted.
Censoring and Follow-up
The Kaplan-Meier and Cox proportional hazard methods
require the implicit assumption that censoring is indepen-
dent of clinical outcomes, which cannot be verified. It is
Surgery for Acquired Cardiovascular Disease Ruel et al
156 The Journal of Thoracic and Cardiovascular Surgery ● January 2004
A
CD
possible that patients lost to follow-up may have had out-
comes that were important but not accounted for in the
analyses or that resulted in their being lost to follow-up.
Furthermore, the median follow-up of the study, although it
extended to 17.1 years, was only 4.3 years. Inferences
therefore apply mostly to intermediate-term outcomes.
Missing Entries
The database contained incomplete entries, for instance,
with respect to echocardiographic data. Missing data were
not imputed, and the sample size of each analysis corre-
sponded to the number of complete entries; this approach
may, however, have prevented the demonstration of some
associations by increasing type II statistical error, because
potential predictors were not all evaluated by using total
samples.
Effective Orifice Area
This study used internal aortic diameters and in vivo EOAs
as primary measures of valve size after aortic valve replace-
ment. This is likely not as accurate as the actual measure-
ments of prosthesis EOA for each patient after operation,
which were not routinely available in the cohort, but the
latter are also more susceptible to errors if low cardiac
output persists after valve replacement.
Inference and Generalizability
This study used a relatively specific composite outcome
based on NYHA class and CHF mortality, but it did not
examine all outcomes that may relate to cardiac perfor-
mance and functional status after valve replacement. No
data were routinely available from the cohort with respect to
exercise tolerance measured by standardized protocols, left
ventricular mass regression, or left ventricular performance
during exercise. Furthermore, to use a composite outcome
of CHF death or symptoms, the cumulative incidence rather
than the prevalence of heart failure was used in the study,
which may have resulted in a seemingly high percentage of
symptomatic patients compared with a prevalence-based
outcome and does not provide an estimate of the duration of
symptoms in affected patients, some of whom may have
experienced durable symptom resolution with medical man-
agement alone.
The findings of this study, like those of other large
observational cohorts, may not necessarily be generalizable
to all patients with prosthetic valves, because the study
represents a single institution’s experience, is not random-
ized, and may have been affected by regional referral and
patient treatment patterns. Unsuspected demographic and
selection factors unique to the study cohort may therefore
have resulted in overfitted statistical associations. Statistical
overfitting was, however, made less likely by the use of
bootstrapped simulations.
Conclusions
This study identified risk factors for the development of
heart failure after aortic valve replacement. Potentially
modifiable factors, such as advanced NYHA class, left
ventricular grade, and increased preoperative pulmonary
diastolic pressures, may be affected by earlier referral for
valve operation. Other risk factors, such as postoperative
tricuspid insufficiency and atrial fibrillation, warrant further
research to better define the effect of concomitant surgical
procedures oriented at these problems on the freedom from
CHF after valve replacement. The findings of this study also
suggest that the implantation of an aortic valve prosthesis
with an estimated iEOA equal to or less than 0.80 cm2/m2
should be avoided whenever feasible, because this results in
a estimated increase in the risk of heart failure after valve
replacement of approximately 60%, despite not significantly
affecting crude long-term survival.
The authors thank Mary Thomson for her assistance with the
organization of the valve clinic and the management of the data-
base.
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Discussion
Dr A. Marc Gillinov (Cleveland, Ohio). Dr Ruel and colleagues
are to be congratulated for this excellent study, which represents an
enormous body of work. There is considerable controversy con-
cerning the impact of prosthesis size in patients receiving aortic
valve replacement, and I will confine my comments to the aortic
valve patients.
We would all like to believe that a larger prosthesis results in
lesser gradients, a greater reduction of left ventricular mass, and
better clinical outcomes, but several recent studies suggest that the
impact of size in modern and hemodynamically efficient prosthe-
ses is limited.
In their assessment of functional outcomes after aortic valve
replacement, Dr Ruel and colleagues identify several risk factors
for CHF. They found that smaller prosthesis size, particularly
when expressed in terms of EOA, was independently associated
with CHF. Although this relationship was generally true at 1 and
5 years after surgery, it was not true at 10 years. I have several
questions related to the method and the conclusions.
First, with respect to patients receiving double valve replace-
ment, both aortic and mitral valves, these patients with 2 affected
left-sided valves may have a worse prognosis than patients with
only an aortic valve replacement. Were patients having only an
aortic valve analyzed separately?
Second, with respect to measures of valve size and patient size,
aortic valve size can be expressed by geometric measures such as
internal orifice diameter and by functional measures such as EOA.
These methods provide somewhat different information, and each
can be indexed to patient size. The EOAs that you used for analysis
were derived from published figures rather than your own patients
in whom you did have echocardiographic data. Why did you use
published figures rather than your own echocardiographic data,
and, in addition, did you index the internal orifice diameter, which
is a geometric dimension that does not change, in your patients?
What were the sizes of the valves implanted? How many
people received valves of labeled size 19 and 21? How common
was prosthesis-patient mismatch if you measure it and call it to be
less than .75 cm2/m2?
I congratulate you and your coauthors on this ambitious study,
which I think is just filled with useful clinical information.
Dr Ruel. Thank you, Dr Gillinov, for your excellent points. In
response to your first question, you are entirely right in that
patients with double valve replacement were not excluded from the
cohort, which therefore included patients who received aortic
valve replacement alone and those who received double valve
replacement. There was no significant difference in the freedom
from CHF between the aortic valve replacement and the aortic
valve replacement plus mitral valve replacement subgroups. In
addition, co-presence of a mitral prosthesis in aortic valve replace-
ment patients was added as one of the multivariate predictors and
was accounted for in the models. (NOTE FROM THE AUTHORS:
Subsequent to this discussion, the analyses and results reported in
this article pertain specifically to patients who had replacement of
the aortic valve alone.)
To answer your second question, measures of prosthesis size
examined in this study had an effect both as an absolute measure-
ment and after being indexed for BSA. In other words, their impact
was significant both as an absolute measure and after indexing for
BSA.
Regarding your point on the use of EOAs, you are absolutely
right in that the values used were the published values, supple-
mented with data from the valve manufacturer. Although there are
limitations to this methodology, because one is not actually mea-
suring the individual EOA of each patient, we believe that there are
several advantages. First, our use of EOA is preferred over the
geometric internal valve area, derived from a simple mathematical
equation that uses the internal diameter of the prosthesis, because
the former measures the physiologic flow area of the prosthesis.
Second, the determination of an individual’s EOA by using Dopp-
ler echocardiography requires an accurate measurement of the left
ventricular outflow tract diameter, outflow tract velocity, and
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transvalvular velocity. These can be difficult to obtain in some
patients because of their body characteristics or because of arti-
facts produced by the prosthesis itself. Our approach is advanta-
geous in that it provides data that can be used clinically to modify
the operative strategy at the time of valve implantation to prevent
patient-prosthesis mismatch.
Coming to your last question with respect to the incidence of
small valves, approximately 2% of the cohort’s patients received
valves of size 19 mm. This increased to approximately 24% of
patients who received either a size 19 or a size 21 aortic valve.
Prosthesis-patient mismatch defined as 0.80 cm2/m2 was prevalent
in approximately 26% of the study population. So, at least in our
practice, mismatch does appear to constitute a significant problem,
since more than one quarter of patients could potentially be pre-
vented from presenting this risk factor for CHF events after aortic
valve replacement. I would like to thank you for your excellent
questions and comments.
Dr Hormoz Azar (Norfolk, Va). Excellent study: congratula-
tions. Considering that patients who had mismatch generally had
more severe aortic stenosis, the question is, for the increased
failure, how much of it was related to previous ventricular fibrosis
and diastolic dysfunction, and how much of it was really related to
the prosthesis mismatch? Did you try to look at the wall thickness
and septal thickness and correlate that in any way?
Dr Ruel. Thank you for your excellent question. Unless there
was strong collinearity, we did not formally ascertain whether
patients who had mismatch also had a higher preoperative preva-
lence of other predictive factors, such as poor left ventricular
grade. We do not know whether a biologic correlation exists
between having a small aortic annulus and having more left
ventricular dysfunction prior to valve replacement. However, an
array of potential confounding factors was accounted for in the
multivariate models, so the impact reported for mismatch or small
valve size is independent of confounders such as preoperative
NYHA class, preoperative left ventricular grade, pulmonary pres-
sures, and so on. However, possible correlations between mis-
match and myocardial thickness measurements after surgery were
not formally examined.
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